[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100630234":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":30,"locations":26,"responsibleParty":36,"collaborators":26,"id":40,"slug":26,"hasResults":41,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":41,"sex":47,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":26,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":26,"overallStatus":59,"whyStopped":26,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":26},{"fullName":5,"class":6},"University of Roma La Sapienza","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Oral Iron Supplementation","EXPERIMENTAL","Participants randomized to this group will begin oral iron therapy immediately after diagnosis. The formulation and dosage will follow institutional practice and guideline recommendations.\n\nPatients will undergo hematologic reassessment at 38+0 weeks of gestation:\n\n* If Hb ≥11 g\u002FdL, oral iron will be continued.\n* If Hb \\\u003C11 g\u002FdL, IV iron will be administered according to standard protocols, as a safety net.",[13],"Drug: Oral iron supplementation",{"label":15,"type":16,"description":17,"interventionNames":18},"IV Iron","ACTIVE_COMPARATOR","Participants randomized to this group will receive IV iron within 7 days of diagnosis. The dose will be calculated based on body weight and estimated iron deficit. Oral iron supplementation is not mandated following IV administration.",[19],"Drug: IV iron administration",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Oral iron supplementation","Participants randomized to this group will begin oral iron therapy immediately after diagnosis. The formulation and dosage will follow institutional practice and guideline recommendations",[9],null,{"type":22,"name":28,"description":17,"armGroupLabels":29,"otherNames":26},"IV iron administration",[15],[31],{"name":32,"role":33,"phone":34,"phoneExt":26,"email":35},"Giuseppe Rizzo, MD","CONTACT","+393386973001","giuseppe.rizzo@uniroma1.it",{"type":37,"investigatorFullName":38,"investigatorTitle":39,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Giuseppe Rizzo","Professor","100630234",false,"NCT07485023","Oral Versus Intravenous Iron for Anemia Diagnosed After 34 Weeks of Gestation","Oral Versus Intravenous Iron for Anemia Diagnosed After 34 Weeks of Gestation: A Randomized Controlled Trial","LAPIS","Inclusion Criteria:\n\n* • Women aged 18 years or older.\n\n  * Singleton pregnancy.\n  * Gestational age ≥34+0 weeks at the time of anemia diagnosis.\n  * Hemoglobin \\\u003C11 g\u002FdL measured as part of routine antenatal care.\n  * Ongoing antenatal follow-up at Policlinico Umberto I.\n  * Ability to understand study procedures and provide written informed consent.\n\nExclusion Criteria:\n\n* • Known anemia not primarily due to iron deficiency.\n\n  * Known hemoglobinopathies.\n  * Severe anemia requiring immediate blood transfusion.\n  * Previous severe hypersensitivity reaction to IV iron formulations.\n  * Chronic hematologic disease.\n  * Acute infection or inflammatory condition at enrollment.\n  * Severe hepatic or renal impairment.\n  * Any condition judged by the investigator to make participation unsafe.","FEMALE","18 Years","50 Years",{"count":51,"type":52},128,"ESTIMATED","INTERVENTIONAL",[55],"NA","This study aims to address this evidence gap by comparing a step-up oral-first strategy with an early IV iron strategy in pregnant women diagnosed with anemia after 34 weeks of gestation.",[58],"Anemia Complicating Pregnancy","NOT_YET_RECRUITING","2026-03-16",{"date":62,"type":63},"2026-03-20","ACTUAL",{"date":65,"type":52},"2026-07-01",{"date":67,"type":52},"2028-09-01",{"name":5,"class":6}]